文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病造血干细胞移植与细胞治疗

骨髓增生异常综合征的临床决策与治疗

Clinical decision-making and treatment of myelodysplastic syndromes.
PubMed 文献 · Blood · 2023-01-01

骨髓增生异常综合征(MDS)是起源于造血干细胞的高度异质性髓系恶性肿瘤,患者管理与治疗同样异质。决策需评估风险、症状并做风险-获益分析。唯一可能治愈手段为异基因干细胞移植,但多数患者不适合。当前挑战包括降低移植失败主因的复发风险。

要点

  • 去甲基化药物(HMA)是高危MDS的一线治疗,联合其他药物一线治疗迄今未证明优于单药。
  • 低危MDS治疗目标是改善血细胞减少(主要为贫血)、生活质量及可能的总体生存。
  • 促红细胞生成素刺激剂(ESA)是贫血一线治疗,在需永久输血前启用反应更好更持久。

核心结论

  • MDS为高度异质性髓系恶性肿瘤,唯一可能治愈手段为异基因干细胞移植,但多数患者不适合。
  • 高危MDS一线治疗为去甲基化药物(HMA),联合其他药物一线治疗迄今未证明优于单药。
  • 低危MDS治疗目标为改善血细胞减少(主要为贫血)、生活质量及可能的总体生存。
  • ESA失败或不适合时,治疗应按主要疾病机制选择:低增生MDS无高危遗传学用免疫抑制,低危del(5q)MDS用来那度胺,伴环形铁粒幼细胞MDS用luspatercept。
  • 需要更好的工具将疾病生物学与治疗匹配(即应用精准医学)以改善患者结局。

研究设计与样本

  • 原文为综述,未报告系统检索范围。

主要发现

  • 去甲基化药物(HMA)为高危MDS一线治疗,联合其他药物一线治疗迄今未证明优于单药。
  • 已获批用于急性髓系白血病的联合方案(包括venetoclax)正在评估中,并常作为挽救治疗使用。
  • ESA为贫血一线治疗,在需永久输血前启用反应更好更持久。
  • ESA失败或不适合时按主要疾病机制选择:低增生MDS无高危遗传学用免疫抑制,低危del(5q)MDS用来那度胺,伴环形铁粒幼细胞MDS用luspatercept。
  • MDS获批治疗选择仍比多数其他血液恶性肿瘤更少。

临床怎么用

  • 决策包括识别个体风险、症状和治疗选项并进行风险-获益分析。
  • ESA应在需永久输血前启用,以获更好更持久反应。
  • ESA失败或不适合时按主要疾病机制选择治疗:低增生MDS无高危遗传学用免疫抑制,低危del(5q)MDS用来那度胺,伴环形铁粒幼细胞MDS用luspatercept。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The myelodysplastic syndromes (MDSs) constitute a profoundly heterogeneous myeloid malignancy with a common origin in the hemopoietic stem cell compartment. Consequently, patient management and treatment are as heterogeneous. Decision-making includes identifying risk, symptoms, and options for an individual and conducting a risk-benefit analysis. The only potential cure is allogeneic stem cell transplantation, and albeit the fraction of patients with MDS who undergo transplant increase over time because of better management and increased donor availability, a majority are not eligible for this intervention. Current challenges encompass to decrease the relapse risk, the main cause of hematopoietic stem cell transplantation failure. Hypomethylating agents (HMAs) constitute firstline treatment for higher-risk MDSs. Combinations with other drugs as firstline treatment has, to date, not proven more efficacious than monotherapy, although combinations approved for acute myeloid leukemia, including venetoclax, are under evaluation and often used as rescue treatment. The treatment goal for lower-risk MDS is to improve cytopenia, mainly anemia, quality of life, and, possibly, overall survival. Erythropoiesis-stimulating agents (ESAs) constitute firstline treatment for anemia and have better and more durable responses if initiated before the onset of a permanent transfusion need. Treatment in case of ESA failure or ineligibility should be tailored to the main disease mechanism: immunosuppression for hypoplastic MDS without high-risk genetics, lenalidomide for low-risk del(5q) MDS, and luspatercept for MDS with ring sideroblasts. Approved therapeutic options are still scarcer for MDS than for most other hematologic malignancies. Better tools to match disease biology with treatment, that is, applied precision medicines are needed to improve patient outcome.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hellström-Lindberg ES, Kröger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023. PMID: 37874917. doi:10.1182/blood.2023020079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。